Biotech cycles can create attractive opportunities when share prices move ahead of the underlying science, especially during weaker market periods. In downturns, smaller drug developers often face tighter funding conditions, high cash burn, and slower regulatory timelines. These pressures can weigh heavily on valuations, even when clinical progress remains intact. In some cases, companies can trade below the value of the cash they hold, creating a clear gap between market pricing and potential asset value.
That gap is important because scientific progress can continue while market sentiment remains weak. Trials can move forward, data can mature, and a therapy can become more de-risked even before the share price reflects that progress. This is one of the reasons biotech cycles can be compelling. The market may focus on near-term funding pressure, while the company continues to build value through clinical development.
A major turning point is often human proof of concept. Phase II clinical data can show whether a therapy works in patients, which is a significant step beyond early safety testing or preclinical research. When a company reaches this stage successfully, its value can be reassessed quickly because the asset is no longer viewed only as a scientific idea. It becomes a more credible clinical opportunity with clearer development potential.
Companies that manage downturns well can therefore emerge in a stronger position. Those with enough cash, disciplined spending, focused programmes, and meaningful upcoming data may be better placed to benefit when sentiment improves. A difficult market can also help separate stronger platforms from weaker ones, directing attention towards companies with the science, management focus, and development strategy needed to progress.
Large pharmaceutical companies add further support to this cycle. Many major drugmakers face patent cliffs as established medicines lose exclusivity and future revenue streams become less secure. This creates ongoing demand for new assets that can refresh pipelines and support future growth. Clinical-stage biotech companies with de-risked therapies can become highly relevant in this environment, particularly when valuations are still low compared with the potential value of their programmes.
Biotech Growth Trust plc (LON:BIOG) seeks capital appreciation through investment in the worldwide biotechnology industry. The Company and the Company’s Portfolio Manager believe that there is a high congruence between companies that seek to act responsibly and those that succeed in building long-term shareholder value.
